202 related articles for article (PubMed ID: 21678351)
41. Exenterative surgery for recurrent gynaecological malignancies.
Ang C; Bryant A; Barton DP; Pomel C; Naik R
Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD010449. PubMed ID: 24497188
[TBL] [Abstract][Full Text] [Related]
42. Tamoxifen for relapse of ovarian cancer.
Williams C; Simera I; Bryant A
Cochrane Database Syst Rev; 2010 Mar; 2010(3):CD001034. PubMed ID: 20238312
[TBL] [Abstract][Full Text] [Related]
43. Getting the MOST out of follow-up: a randomized controlled trial comparing 3 monthly nurse led follow-up via telehealth, including monitoring CA125 and patient reported outcomes using the MOST (Measure of Ovarian Symptoms and Treatment concerns) with routine clinic based or telehealth follow-up, after completion of first line chemotherapy in patients with epithelial ovarian cancer.
Cohen PA; Webb PM; King M; Obermair A; Gebski V; Butow P; Morton R; Lawson W; Yates P; Campbell R; Meniawy T; McMullen M; Dean A; Goh J; McNally O; Mileshkin L; Beale P; Beach R; Hill J; Dixon C; Hegarty S; Codde J; Ives A; Lee YC; Brand A; Mellon A; Bilic S; Black I; Jeffares S; Friedlander M
Int J Gynecol Cancer; 2022 Apr; 32(4):560-565. PubMed ID: 34551895
[TBL] [Abstract][Full Text] [Related]
44. Obesity and epithelial ovarian cancer survival: a systematic review and meta-analysis.
Bae HS; Kim HJ; Hong JH; Lee JK; Lee NW; Song JY
J Ovarian Res; 2014; 7():41. PubMed ID: 24834130
[TBL] [Abstract][Full Text] [Related]
45. Perioperative enhanced recovery programmes for gynaecological cancer patients.
Lu D; Wang X; Shi G
Cochrane Database Syst Rev; 2015 Mar; 2015(3):CD008239. PubMed ID: 25789452
[TBL] [Abstract][Full Text] [Related]
46. Delayed Versus Immediate Start of Chemotherapy in Asymptomatic Patients With Advanced Cancer: A Meta-Analysis.
Augustinus S; Thurairajah G; Besselink MG; van Laarhoven HWM; van Oijen MGH; Mackay TM; Wilmink JW
Oncologist; 2023 Nov; 28(11):961-968. PubMed ID: 37589234
[TBL] [Abstract][Full Text] [Related]
47. Non-Surgical Management of Malignant Bowel Obstruction in Advanced Ovarian Cancer patients: A Systematic Review and Meta-Analysis.
Idaikkadar P; Georgiou A; Skene S; Michael A
Am J Hosp Palliat Care; 2022 Jul; 39(7):838-846. PubMed ID: 34490792
[TBL] [Abstract][Full Text] [Related]
48. Knowledge and attitudes towards clinical trials among women with ovarian cancer: results of the ACTO study.
Mosconi P; Roberto A; Cerana N; Colombo N; Didier F; D'Incalci M; Lorusso D; Peccatori FA;
J Ovarian Res; 2022 Apr; 15(1):45. PubMed ID: 35422000
[TBL] [Abstract][Full Text] [Related]
49. Potential Strategies to Increase Gynecologic Oncologist Treatment for Ovarian Cancer.
Stewart SL; Mezzo JL; Nielsen D; Rim SH; Moore AR; Bhalakia A; House M
J Womens Health (Larchmt); 2021 Jun; 30(6):769-781. PubMed ID: 34128688
[TBL] [Abstract][Full Text] [Related]
50. Identification of biomarkers for the diagnosis and targets for therapy in patients with clear cell ovarian cancer: a systematic literature review.
Butler H; Saulat O; Guinn BA
Carcinogenesis; 2022 Apr; 43(3):183-189. PubMed ID: 35104328
[TBL] [Abstract][Full Text] [Related]
51. Evaluation of follow-up strategies for patients with epithelial ovarian cancer following completion of primary treatment.
Clarke T; Galaal K; Bryant A; Naik R
Cochrane Database Syst Rev; 2014 Sep; 2014(9):CD006119. PubMed ID: 25198378
[TBL] [Abstract][Full Text] [Related]
52. Evaluation of follow-up strategies for women with epithelial ovarian cancer following completion of primary treatment.
Zachou G; El-Khouly F; Dilley J
Cochrane Database Syst Rev; 2023 Aug; 8(8):CD006119. PubMed ID: 37650760
[TBL] [Abstract][Full Text] [Related]
53. Proactive use of PROMs in ovarian cancer survivors: a systematic review.
Kargo AS; Coulter A; Jensen PT; Steffensen KD
J Ovarian Res; 2019 Jul; 12(1):63. PubMed ID: 31307510
[TBL] [Abstract][Full Text] [Related]
54. Trial of Optimal Personalised Care After Treatment for Gynaecological cancer (TOPCAT-G): a study protocol for a randomised feasibility trial.
Pye K; Totton N; Stuart N; Whitaker R; Morrison V; Edwards RT; Yeo ST; Timmis LJ; Butterworth C; Hall L; Rai T; Hoare Z; Neal RD; Wilkinson C; Leeson S
Pilot Feasibility Stud; 2016; 2():67. PubMed ID: 27965882
[TBL] [Abstract][Full Text] [Related]
55. Surveillance and Care of the Gynecologic Cancer Survivor.
Faubion SS; MacLaughlin KL; Long ME; Pruthi S; Casey PM
J Womens Health (Larchmt); 2015 Nov; 24(11):899-906. PubMed ID: 26208166
[TBL] [Abstract][Full Text] [Related]
56. Positron Emission Tomography (PET) in Oncology.
Gallamini A; Zwarthoed C; Borra A
Cancers (Basel); 2014 Sep; 6(4):1821-89. PubMed ID: 25268160
[TBL] [Abstract][Full Text] [Related]
57. S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours: Short version 1.0 - AWMF registration number: 032/035OL, June 2013.
Wagner U; Harter P; Hilpert F; Mahner S; Reuß A; du Bois A; Petru E; Meier W; Ortner P; König K; Lindel K; Grab D; Piso P; Ortmann O; Runnebaum I; Pfisterer J; Lüftner D; Frickhofen N; Grünwald F; Maier BO; Diebold J; Hauptmann S; Kommoss F; Emons G; Radeleff B; Gebhardt M; Arnold N; Calaminus G; Weisse I; Weis J; Sehouli J; Fink D; Burges A; Hasenburg A; Eggert C
Geburtshilfe Frauenheilkd; 2013 Sep; 73(9):874-889. PubMed ID: 24771937
[No Abstract] [Full Text] [Related]
58. Current approaches and challenges in managing and monitoring treatment response in ovarian cancer.
Marcus CS; Maxwell GL; Darcy KM; Hamilton CA; McGuire WP
J Cancer; 2014 Jan; 5(1):25-30. PubMed ID: 24396495
[TBL] [Abstract][Full Text] [Related]
59. Gynaecological cancer follow-up: national survey of current practice in the UK.
Leeson S; Stuart N; Sylvestre Y; Hall L; Whitaker R
BMJ Open; 2013; 3(7):. PubMed ID: 23883880
[TBL] [Abstract][Full Text] [Related]
60. Latest research and treatment of advanced-stage epithelial ovarian cancer.
Coleman RL; Monk BJ; Sood AK; Herzog TJ
Nat Rev Clin Oncol; 2013 Apr; 10(4):211-24. PubMed ID: 23381004
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
